The Global Shingles Vaccine Market is Witnessing Rapid Influx of Newer and Expensive Products
Herpes zoster, another name for
shingles, is a viral infection that damages the brain-originating cranial
nerves. It is brought on by the same virus that causes chicken pox, varicella
zoster. Anyone who has had chicken pox in the past has the risk of acquiring
shingles since the virus can remain dormant in the body for many years.
The main factor driving the
growth of the shingles
vaccine market is the rising incidence and prevalence of shingles.
Demand for shingles vaccinations has been sparked by an ageing population as
well as the rising approval and introduction of improved shingles vaccines. For
instance, the national medical administration in August 2019 approved GSK's
Shingrix vaccine for the prevention of shingles in adults, following the
European Commission's approval in 2018. The variables that are anticipated to
assist the expansion of the market also include escalating government
initiatives and an increase in healthcare awareness. The market's expansion is
being held back by the shingle vaccine's expensive price, though.
For its Shingrix shingles
vaccine, GlaxoSmithKline (GSK), a market leader in vaccines, applied for U.S.
FDA approval in October 2016. In its clinical studies, Shingrix outperformed
Zostavax in terms of results. In those over 70, the vaccination had a 90% success
rate. The vaccine was shown to be 97% effective all around. Its greater
efficacy, even among the elderly population, is anticipated to promote its use
globally. This outstanding trail performance would give Shingrix a significant
competitive advantage in the existing Zostavax-dominated worldwide market.
According to reports, the corporation requested regulatory permissions for the
markets of Europe and Canada in 2016 and Japan in 2017.
Comments
Post a Comment